Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive expansion during tumor progression. These cells not only support immune escape directly but also promote tumor invasion via various non-immunological...

Full description

Saved in:
Bibliographic Details
Published inSignal transduction and targeted therapy Vol. 6; no. 1; pp. 362 - 25
Main Authors Li, Kai, Shi, Houhui, Zhang, Benxia, Ou, Xuejin, Ma, Qizhi, Chen, Yue, Shu, Pei, Li, Dan, Wang, Yongsheng
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 07.10.2021
Nature Publishing Group
Subjects
631/67/327
631/67/580
Antitumor agents
Cancer
Cancer Research
Cancer therapies
Cell Biology
Chemotherapy
Clinical trials
Humans
Immune Tolerance - immunology
Immunosuppressive Agents - therapeutic use
Immunotherapy
Internal Medicine
Medicine
Medicine & Public Health
Myeloid cells
Myeloid-Derived Suppressor Cells - immunology
Myeloid-Derived Suppressor Cells - transplantation
Neoplasms - immunology
Neoplasms - therapy
Oncology
Pathology
Radiation therapy
Review
Review Article
Suppressor cells
Therapeutic applications
Tumor Escape - immunology
Tumor Microenvironment - immunology
Online AccessGet full text

Cover

More Information
Summary:Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive expansion during tumor progression. These cells not only support immune escape directly but also promote tumor invasion via various non-immunological activities. Besides, this group of cells are proved to impair the efficiency of current antitumor strategies such as chemotherapy, radiotherapy, and immunotherapy. Therefore, MDSCs are considered as potential therapeutic targets for cancer therapy. Treatment strategies targeting MDSCs have shown promising outcomes in both preclinical studies and clinical trials when administrated alone, or in combination with other anticancer therapies. In this review, we shed new light on recent advances in the biological characteristics and immunosuppressive functions of MDSCs. We also hope to propose an overview of current MDSCs-targeting therapies so as to provide new ideas for cancer treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2059-3635
2095-9907
2059-3635
DOI:10.1038/s41392-021-00670-9